Revista Iberoamericana De Micologia最新文献

英文中文

Guttural pouch mycosis, sympathy for Aspergillus nidulans 咽喉袋真菌病，与细曲霉同感

IF 1.9 4区生物学 Q4 MYCOLOGY

Revista Iberoamericana De Micologia

Pub Date : 2020-07-01 DOI: 10.1016/j.riam.2020.01.002

F. Javier Cabañes

引用次数: 1

Synergistic interactions between β-lapachone and fluconazole in the inhibition of CaCdr2p and CaMdr1p in Candida albicans β-拉帕酮与氟康唑对白色念珠菌CaCdr2p和CaMdr1p抑制的协同作用

IF 1.9 4区生物学 Q4 MYCOLOGY

Revista Iberoamericana De Micologia

Pub Date : 2020-07-01 DOI: 10.1016/j.riam.2020.09.002

Daniel Clemente Moraes , Leandro Figueira Reis de Sá , Levy Tenorio Sousa Domingos , Maria do Carmo Freire Ribeiro Pinto , Rosangela Maria de Araújo Soares , Antônio Ferreira-Pereira

Background

Mortality rate of invasive Candida infections is raising mainly amongst immunocompromised patients. These infections are hard-to-treat mainly due to the increasing incidence of resistance. The overexpression of ATP-binding cassette and major facilitator superfamily transporters is the main responsible for the failure of antifungal therapies. In a Saccharomyces cerevisiae model, β-lapachone inhibited Pdr5p, a transporter homologous to those found in Candida albicans.

Aims

To determine whether β-lapachone reverses the resistance phenotype mediated by efflux transporters in C. albicans clinical isolates.

Methods

The antifungal activity of β-lapachone combined with fluconazole was measured by agarose chemosensitization and microdilution assays. CaCdr2p and CaMdr1p activities were evaluated through fluorescent dyes accumulation. ATPase activity was assessed using transporter-enriched plasma membranes.

Results

β-lapachone reverted antifungal resistance of S. cerevisiae and C. albicans strains overexpressing CaCdr2p and CaMdr1p transporters by inhibiting these proteins activities. CaCdr2p ATPase activity was not impaired by the compound.

Conclusions

β-lapachone is a promising drug candidate to be used as an adjuvant in the treatment of candidiasis caused by fluconazole-resistant C. albicans strains.

背景:侵袭性念珠菌感染的死亡率主要在免疫功能低下的患者中上升。这些感染难以治疗，主要是由于耐药发生率增加。atp结合盒和主要促进剂超家族转运蛋白的过表达是抗真菌治疗失败的主要原因。在酿酒酵母模型中，β-lapachone抑制Pdr5p，一种与白色念珠菌同源的转运体。目的探讨β-lapachone能否逆转白念珠菌临床分离株外排转运体介导的耐药表型。方法采用琼脂糖化学增敏法和微量稀释法测定β-拉帕酮与氟康唑联合抑菌活性。通过荧光染料积累法测定CaCdr2p和CaMdr1p活性。利用富含转运蛋白的质膜评估atp酶活性。结果β-lapachone通过抑制CaCdr2p和CaMdr1p转运体的活性，恢复了酿酒葡萄球菌和白色念珠菌的抗真菌能力。CaCdr2p atp酶活性未被该化合物破坏。结论β-拉帕酮是治疗耐氟康唑白色念珠菌引起的念珠菌病的一种有前景的佐剂药物。

{"title":"Synergistic interactions between β-lapachone and fluconazole in the inhibition of CaCdr2p and CaMdr1p in Candida albicans","authors":"Daniel Clemente Moraes , Leandro Figueira Reis de Sá , Levy Tenorio Sousa Domingos , Maria do Carmo Freire Ribeiro Pinto , Rosangela Maria de Araújo Soares , Antônio Ferreira-Pereira","doi":"10.1016/j.riam.2020.09.002","DOIUrl":"10.1016/j.riam.2020.09.002","url":null,"abstract":"<div><h3>Background</h3><p>Mortality rate of invasive <em>Candida</em> infections is raising mainly amongst immunocompromised patients. These infections are hard-to-treat mainly due to the increasing incidence of resistance. The overexpression of ATP-binding cassette and major facilitator superfamily transporters is the main responsible for the failure of antifungal therapies. In a <span><em>Saccharomyces cerevisiae</em></span> model, β-lapachone inhibited Pdr5p, a transporter homologous to those found in <span><em>Candida albicans</em></span>.</p></div><div><h3>Aims</h3><p>To determine whether β-lapachone reverses the resistance phenotype mediated by efflux transporters in <em>C</em>. <em>albicans</em> clinical isolates.</p></div><div><h3>Methods</h3><p>The antifungal activity of β-lapachone combined with fluconazole was measured by agarose chemosensitization and microdilution assays. CaCdr2p and CaMdr1p activities were evaluated through fluorescent dyes accumulation. ATPase activity was assessed using transporter-enriched plasma membranes.</p></div><div><h3>Results</h3><p>β-lapachone reverted antifungal resistance of <em>S. cerevisiae</em> and <em>C. albicans</em> strains overexpressing CaCdr2p and CaMdr1p transporters by inhibiting these proteins activities. CaCdr2p ATPase activity was not impaired by the compound.</p></div><div><h3>Conclusions</h3><p><span>β-lapachone is a promising drug candidate to be used as an adjuvant in the treatment of candidiasis caused by fluconazole-resistant </span><em>C. albicans</em> strains.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":"37 3","pages":"Pages 104-106"},"PeriodicalIF":1.9,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2020.09.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40455514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Bat white-nose syndrome: A devastating epizootic in North America 蝙蝠白鼻综合征:北美一种毁灭性的动物流行病

IF 1.9 4区生物学 Q4 MYCOLOGY

Revista Iberoamericana De Micologia

Pub Date : 2020-07-01 DOI: 10.1016/j.riam.2020.01.003

F. Javier Cabañes

引用次数: 0

Recent changes in candidemia trends in a tertiary hospital (2011–2018) 某三级医院念珠菌流行趋势近期变化(2011-2018年)

IF 1.9 4区生物学 Q4 MYCOLOGY

Revista Iberoamericana De Micologia

Pub Date : 2020-07-01 DOI: 10.1016/j.riam.2020.09.005

Ana I. Piqueras , Thomas Rubio , Eva M. Lopez-Medina , Ana Gimeno , Vicent Modesto , Emilia Cantón , Javier Pemán

Background

The epidemiology of candidemia has changed over the last decades and varies widely among geographic areas.

Aims

We examined in children (aged 0–14) with candidemia the trends in the incidence rate of this infection, as well as the clinical characteristics of the patients, in order to optimize the prognosis and the control measures of this serious disease.

Methods

A retrospective cohort study of candidemia in the period 2011–2018 in the neonatal intensive care unit (NICU), pediatric ICU (PICU) and pediatric wards of a tertiary hospital, was conducted. The clinical course, Candida species isolated, antifungal susceptibility, outcome and incidence rates were analyzed and compared.

Results

We diagnosed 68 episodes of candidemia in 62 children, 48% occurred in the NICU, 31% in the PICU and 21% in pediatric wards. Candida albicans was the most frequent species isolated in NICU infants (53%), and Candida parapsilosis predominated among PICU patients (59%) and pediatric wards (50%). One third of NICU infants had invasive candidiasis (IC), most of them having extremely low birth weight (ELBW) (35%). All isolates were susceptible to the antifungal administered. Over time, the incidence of candidemia decreased in the PICU (from 2.2 to 0.3 episodes/1000 patient-days, OR = 0.6; 95%CI 0.5–0.8), whereas in the NICU and in the wards remained stable. Mortality occurred mostly in NICU patients (26%), predominated in ELBW infants and did not change over time.

Conclusions

The higher incidence and mortality of candidemia and IC observed in preterm infants requires a continuous evaluation of practices and diagnostic methods which will allow improving the prognosis of this most vulnerable population.

背景念珠菌的流行病学在过去几十年中发生了变化，在地理区域之间差异很大。目的探讨0 ~ 14岁儿童念珠菌感染的发病率变化趋势及患者的临床特点，为优化这一严重疾病的预后和控制措施提供依据。方法对某三级医院2011-2018年新生儿重症监护病房(NICU)、儿科重症监护病房(PICU)和儿科病房的念珠菌病进行回顾性队列研究。分析比较两组患者的临床病程、分离到的念珠菌种类、抗真菌药敏、转归及发病率。结果62例患儿共确诊68例念珠菌，其中NICU患者占48%，PICU患者占31%，儿科病房患者占21%。白色念珠菌是NICU婴儿中最常见的菌种(53%)，假丝酵母菌在PICU患者(59%)和儿科病房(50%)中占主导地位。三分之一的新生儿患有侵袭性念珠菌病(IC)，其中大多数为极低出生体重(ELBW)(35%)。所有分离株均对抗真菌药敏感。随着时间的推移，PICU内念珠菌的发病率下降(从2.2次/1000患者-天降至0.3次/1000患者-天，OR = 0.6;95%CI 0.5-0.8)，而在NICU和病房则保持稳定。死亡率主要发生在NICU患者中(26%)，主要发生在低体重婴儿中，并且没有随时间变化。结论:在早产儿中观察到念珠菌和IC的较高发病率和死亡率，需要对实践和诊断方法进行持续评估，以改善这一最脆弱人群的预后。

{"title":"Recent changes in candidemia trends in a tertiary hospital (2011–2018)","authors":"Ana I. Piqueras , Thomas Rubio , Eva M. Lopez-Medina , Ana Gimeno , Vicent Modesto , Emilia Cantón , Javier Pemán","doi":"10.1016/j.riam.2020.09.005","DOIUrl":"10.1016/j.riam.2020.09.005","url":null,"abstract":"<div><h3>Background</h3><p>The epidemiology of candidemia has changed over the last decades and varies widely among geographic areas.</p></div><div><h3>Aims</h3><p>We examined in children (aged 0–14) with candidemia the trends in the incidence rate of this infection, as well as the clinical characteristics of the patients, in order to optimize the prognosis and the control measures of this serious disease.</p></div><div><h3>Methods</h3><p>A retrospective cohort study of candidemia in the period 2011–2018 in the neonatal intensive care unit (NICU), pediatric ICU (PICU) and pediatric wards of a tertiary hospital, was conducted. The clinical course, <em>Candida</em> species isolated, antifungal susceptibility, outcome and incidence rates were analyzed and compared.</p></div><div><h3>Results</h3><p>We diagnosed 68 episodes of candidemia in 62 children, 48% occurred in the NICU, 31% in the PICU and 21% in pediatric wards. <span><em>Candida albicans</em></span> was the most frequent species isolated in NICU infants (53%), and <span><em>Candida parapsilosis</em></span><span> predominated among PICU patients (59%) and pediatric wards (50%). One third of NICU infants had invasive candidiasis (IC), most of them having extremely low birth weight (ELBW) (35%). All isolates were susceptible to the antifungal administered. Over time, the incidence of candidemia decreased in the PICU (from 2.2 to 0.3 episodes/1000 patient-days, OR</span>  <!-->0.6; 95%CI 0.5–0.8), whereas in the NICU and in the wards remained stable. Mortality occurred mostly in NICU patients (26%), predominated in ELBW infants and did not change over time.</p></div><div><h3>Conclusions</h3><p>The higher incidence and mortality of candidemia and IC observed in preterm infants requires a continuous evaluation of practices and diagnostic methods which will allow improving the prognosis of this most vulnerable population.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":"37 3","pages":"Pages 87-93"},"PeriodicalIF":1.9,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2020.09.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38339678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Infección fúngica sinusal por Schizophyllum commune: a propósito de dos casos clínicos 常见裂叶菌鼻窦真菌感染:两例临床病例的综述

IF 1.9 4区生物学 Q4 MYCOLOGY

Revista Iberoamericana De Micologia

Pub Date : 2020-04-01 DOI: 10.1016/j.riam.2020.02.004

Belén Fernández-Caso , Arturo Manuel Fraile , Marta Soledad Rodríguez , Inmaculada Fernández , Buenaventura Buendía

Background

Schizophyllum commune is a basidiomycete fungus which is widely distributed in nature. Its role as responsible for disease in humans is not well known, partly due to its difficult identification. The incorporation of mass spectrometry techniques (MALDI-TOF) and molecular biology to the laboratories has allowed the description of a greater number of cases.

Case report

In this paper, we present two cases in which S. commune was identified as the causative agent of disease: in the first case an immunocompetent patient suffered from chronic rhinosinusitis, and in the second one a sphenoid sinus infection was diagnosed in an immunocompromised patient. In both cases, S. commune was isolated. Its identification was possible by means of MALDI-TOF and this was confirmed in both patients by amplification and sequencing of the ITS region.

Conclusions

In conclusion, S. commune should be considered a potential causative agent of fungal disease. Currently, MALDI-TOF and sequencing techniques are necessary for its identification.

裂叶菌(schizophyllum commune)是一种广泛分布于自然界的担子真菌。它在人类疾病中的作用尚不清楚，部分原因是它难以识别。将质谱分析技术(MALDI-TOF)和分子生物学结合到实验室，可以对更多的病例进行描述。在这篇论文中，我们提出了两例被确定为疾病病原体的S. commune:在第一例中，一名免疫功能正常的患者患有慢性鼻窦炎，在第二例中，一名免疫功能低下的患者被诊断为蝶窦感染。在这两种情况下，S. commune都被隔离。可以通过MALDI-TOF进行鉴定，并通过Its区域的扩增和测序在两例患者中得到证实。结论:该菌为真菌病的潜在病原。目前，需要利用MALDI-TOF和测序技术进行鉴定。

{"title":"Infección fúngica sinusal por Schizophyllum commune: a propósito de dos casos clínicos","authors":"Belén Fernández-Caso , Arturo Manuel Fraile , Marta Soledad Rodríguez , Inmaculada Fernández , Buenaventura Buendía","doi":"10.1016/j.riam.2020.02.004","DOIUrl":"10.1016/j.riam.2020.02.004","url":null,"abstract":"<div><h3>Background</h3><p><em>Schizophyllum commune</em> is a basidiomycete fungus which is widely distributed in nature. Its role as responsible for disease in humans is not well known, partly due to its difficult identification. The incorporation of mass spectrometry techniques (MALDI-TOF) and molecular biology to the laboratories has allowed the description of a greater number of cases.</p></div><div><h3>Case report</h3><p>In this paper, we present two cases in which <em>S. commune</em> was identified as the causative agent of disease: in the first case an immunocompetent patient suffered from chronic rhinosinusitis, and in the second one a sphenoid sinus infection was diagnosed in an immunocompromised patient. In both cases, <em>S. commune</em> was isolated. Its identification was possible by means of MALDI-TOF and this was confirmed in both patients by amplification and sequencing of the ITS region.</p></div><div><h3>Conclusions</h3><p>In conclusion, <em>S. commune</em> should be considered a potential causative agent of fungal disease. Currently, MALDI-TOF and sequencing techniques are necessary for its identification.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":"37 2","pages":"Pages 65-67"},"PeriodicalIF":1.9,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2020.02.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37909114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Micosis pulmonares en pacientes con diabetes mellitus. Características clínicas y factores de riesgo 糖尿病患者肺真菌病。临床特征及危险因素

IF 1.9 4区生物学 Q4 MYCOLOGY

Revista Iberoamericana De Micologia

Pub Date : 2020-04-01 DOI: 10.1016/j.riam.2020.04.002

Alejandro Hernández-Solís , Alejandra Camerino Guerrero , Yesenia Colín Muñoz , Saret Bazán Cuervo , Raúl Cícero Sabido , Arturo Reding-Bernal

Background

Diabetes mellitus is a public health problem in Mexico, and the trend of the disease is increasing. From 2000 to 2017, 7.32 million new cases were diagnosed, with pulmonary mycoses being one of the most serious complications.

Aims

To describe the frequency and the clinical characteristics of patients diagnosed with pulmonary mycoses, and to identify the risk factors associated with this entity.

Methods

Case–control study, paired by gender (1:1-3) and age (± 5 years), that analyzed patients with pulmonary mycosis (mucormycosis, histoplasmosis, coccidioidomycosis, blastomycosis, aspergillosis, cryptococcosis, paracoccidioidomycosis) and studied the risk factors present in each patient.

Results

From the 162 patients studied, 56 suffered pulmonary mycosis and 106 were controls. The median of the age was 51 and 50 years for the cases and for the controls, respectively. Multiple logistic regression analysis showed that patients with diabetes mellitus had an odds ratio of 8,3 (p < 0.001), and patients with a history of tuberculosis had an odds ratio of 8,8 (p < 0.001).

Conclusions

Our results show that 52% of the patients with pulmonary mycoses had a history of diabetes mellitus. Diabetes mellitus is a relevant risk factor for pulmonary mycoses, which are usually diagnosed in advanced stages and have a high mortality.

糖尿病是墨西哥的一个公共卫生问题，而且发病率呈上升趋势。从2000年到2017年，新增确诊病例732万例，其中肺真菌病是最严重的并发症之一。目的描述诊断为肺真菌病的患者的频率和临床特征，并确定与该实体相关的危险因素。方法病例对照研究，按性别(1:1-3)和年龄(±5岁)配对，分析肺真菌病(毛霉病、组织胞浆菌病、球孢子菌病、芽生菌病、曲霉病、隐球菌病、副球孢子菌病)患者，并分析每个患者存在的危险因素。结果162例患者中56例为肺真菌病，106例为对照组。病例和对照组的中位年龄分别为51岁和50岁。多元logistic回归分析显示，糖尿病患者的优势比为8,3 (p <0.001)，有结核病史的患者的优势比为8,8 (p <0.001)。结论结果显示，52%的肺真菌病患者有糖尿病病史。糖尿病是肺真菌病的相关危险因素，通常在晚期诊断出来，死亡率很高。

{"title":"Micosis pulmonares en pacientes con diabetes mellitus. Características clínicas y factores de riesgo","authors":"Alejandro Hernández-Solís , Alejandra Camerino Guerrero , Yesenia Colín Muñoz , Saret Bazán Cuervo , Raúl Cícero Sabido , Arturo Reding-Bernal","doi":"10.1016/j.riam.2020.04.002","DOIUrl":"10.1016/j.riam.2020.04.002","url":null,"abstract":"<div><h3>Background</h3><p>Diabetes mellitus is a public health problem in Mexico, and the trend of the disease is increasing. From 2000 to 2017, 7.32 million new cases were diagnosed, with pulmonary mycoses being one of the most serious complications.</p></div><div><h3>Aims</h3><p>To describe the frequency and the clinical characteristics of patients diagnosed with pulmonary mycoses, and to identify the risk factors associated with this entity.</p></div><div><h3>Methods</h3><p>Case–control study, paired by gender (1:1-3) and age (± 5 years), that analyzed patients with pulmonary mycosis (mucormycosis, histoplasmosis, coccidioidomycosis, blastomycosis, aspergillosis, cryptococcosis, paracoccidioidomycosis) and studied the risk factors present in each patient.</p></div><div><h3>Results</h3><p>From the 162 patients studied, 56 suffered pulmonary mycosis and 106 were controls. The median of the age was 51 and 50 years for the cases and for the controls, respectively. Multiple logistic regression analysis showed that patients with diabetes mellitus had an odds ratio of 8,3 <em>(p</em> < 0.001), and patients with a history of tuberculosis had an odds ratio of 8,8 <em>(p</em> < 0.001).</p></div><div><h3>Conclusions</h3><p>Our results show that 52% of the patients with pulmonary mycoses had a history of diabetes mellitus. Diabetes mellitus is a relevant risk factor for pulmonary mycoses, which are usually diagnosed in advanced stages and have a high mortality.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":"37 2","pages":"Pages 53-57"},"PeriodicalIF":1.9,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2020.04.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38113315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Actividad antifúngica de los enjuagues bucales frente a Candida albicans y Rhodotorula mucilaginosa: un estudio in vitro 漱口水对白色念珠菌和黏液红藻的抗真菌活性:一项体外研究

IF 1.9 4区生物学 Q4 MYCOLOGY

Revista Iberoamericana De Micologia

Pub Date : 2020-04-01 DOI: 10.1016/j.riam.2019.10.006

Rodrigo Alejandro Handschuh Briones , Evelyn Nicole Silva Arcos , Milton Urrutia , Patricio Godoy-Martínez

Background

Candida albicans and Rhodotorula mucilaginosa are yeasts of clinical importance in the oral cavity. In immunocompromised patients they can cause some pathologies that must be controlled with antimicrobials.

Aims

To evaluate and compare the antimicrobial efficacy of commercially available mouthrinses against strains of C. albicans and R. mucilaginosa.

Methods

The six mouthwashes studied in vitro were formulated (alone or in combination) with chlorhexidine (CHX) 0.12%, CHX 0.1%, CHX 0.05%, cetylpyridinium chloride (CPC) 0.075%, CPC 0.05%, and essential oils. Ten C. albicans and R. mucilaginosa isolates each were studied. The agar diffusion method (Mueller Hinton II), with incubation at 32 °C was used to evaluate the antifungal activity.

Results

The results of this study indicate that mouthwashes with CHX 0.1%, CHX 0.12%, CHX 0.05% + CPC 0.05%, CHX 0.12% + CPC 0.05% and CPC 0.075% have an antifungal effect against C. albicans and R. mucilaginosa. CHX 0.1% led to the broadest inhibition zone for C. albicans and R. mucilaginosa (25.65 ± 2.39 mm and 40.05 ± 3.31 mm). Essential oils did not show any antifungal activity. Statistical analysis showed no statistical difference between mouth rinses CHX 0.1%, CHX 0.12% and CHX 0.12% + CPC 0.05% (p = 0.0001) against C. albicans and R. mucilaginosa.

Conclusions

Mouthwashes with CHX showed higher antifungal activity against C. albicans and R. mucilaginosa than other mouthwashes studied.

背景白色念珠菌和粘液红酵母是口腔中具有重要临床意义的酵母菌。在免疫功能低下的患者中，它们可引起一些必须用抗菌素控制的病理。目的评价和比较市售漱口水对白色念珠菌和黏液念珠菌的抑菌效果。方法分别以氯己定(CHX) 0.12%、CHX 0.1%、CHX 0.05%、氯化十六烷基吡啶(CPC) 0.075%、CPC 0.05%、香精油配制6种体外漱口水(单独或联合配制)。研究了10株白色念珠菌和黏液念珠菌。采用琼脂扩散法(Mueller Hinton II)，在32°C孵育下评估其抗真菌活性。结果CHX 0.1%、CHX 0.12%、CHX 0.05% + CPC 0.05%、CHX 0.12% + CPC 0.05%和CPC 0.075%漱口水对白色念珠菌和黏液念珠菌均有抑菌作用。CHX 0.1%对白色念珠菌和黏液念珠菌的抑制区最宽(25.65±2.39 mm和40.05±3.31 mm)。精油没有显示出任何抗真菌活性。统计分析显示，CHX 0.1%、CHX 0.12%和CHX 0.12% + CPC 0.05%漱口水对白色念珠菌和黏液念珠菌的抑制作用无统计学差异(p = 0.0001)。结论CHX漱口水对白色念珠菌和黏液念珠菌的抑菌活性高于其他漱口水。

{"title":"Actividad antifúngica de los enjuagues bucales frente a Candida albicans y Rhodotorula mucilaginosa: un estudio in vitro","authors":"Rodrigo Alejandro Handschuh Briones , Evelyn Nicole Silva Arcos , Milton Urrutia , Patricio Godoy-Martínez","doi":"10.1016/j.riam.2019.10.006","DOIUrl":"10.1016/j.riam.2019.10.006","url":null,"abstract":"<div><h3>Background</h3><p><em>Candida albicans</em> and <em>Rhodotorula mucilaginosa</em> are yeasts of clinical importance in the oral cavity. In immunocompromised patients they can cause some pathologies that must be controlled with antimicrobials.</p></div><div><h3>Aims</h3><p>To evaluate and compare the antimicrobial efficacy of commercially available mouthrinses against strains of <em>C. albicans</em> and <em>R. mucilaginosa</em>.</p></div><div><h3>Methods</h3><p>The six mouthwashes studied <em>in vitro</em> were formulated (alone or in combination) with chlorhexidine (CHX) 0.12%, CHX 0.1%, CHX 0.05%, cetylpyridinium chloride (CPC) 0.075%, CPC 0.05%, and essential oils. Ten <em>C. albicans</em> and <em>R. mucilaginosa</em> isolates each were studied. The agar diffusion method (Mueller Hinton II), with incubation at 32°C was used to evaluate the antifungal activity.</p></div><div><h3>Results</h3><p>The results of this study indicate that mouthwashes with CHX 0.1%, CHX 0.12%, CHX 0.05% + CPC 0.05%, CHX 0.12% + CPC 0.05% and CPC 0.075% have an antifungal effect against <em>C. albicans</em> and <em>R. mucilaginosa</em>. CHX 0.1% led to the broadest inhibition zone for <em>C. albicans</em> and <em>R. mucilaginosa</em> (25.65±2.39mm and 40.05±3.31mm). Essential oils did not show any antifungal activity. Statistical analysis showed no statistical difference between mouth rinses CHX 0.1%, CHX 0.12% and CHX 0.12% + CPC 0.05% (<em>p</em>  <!-->0.0001) against <em>C. albicans</em> and <em>R. mucilaginosa</em>.</p></div><div><h3>Conclusions</h3><p>Mouthwashes with CHX showed higher antifungal activity against <em>C. albicans</em> and <em>R. mucilaginosa</em> than other mouthwashes studied.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":"37 2","pages":"Pages 47-52"},"PeriodicalIF":1.9,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2019.10.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38198998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tsunamis and changes in the etiology of the canine and feline cryptococcosis 海啸和犬猫隐球菌病病因学的变化

IF 1.9 4区生物学 Q4 MYCOLOGY

Revista Iberoamericana De Micologia

Pub Date : 2020-04-01 DOI: 10.1016/j.riam.2019.12.002

F. Javier Cabañes

引用次数: 0

Rhodotorula dairenensis fungemia in a patient with cancer 癌症患者的戴氏红酵母菌血症

IF 1.9 4区生物学 Q4 MYCOLOGY

Revista Iberoamericana De Micologia

Pub Date : 2020-04-01 DOI: 10.1016/j.riam.2020.03.006

Fernando Cobo , Óscar Zaragoza , José María Navarro-Marí

Background

Rhodotorula species were traditionally considered non-virulent environmental microorganisms, but are nowadays considered important human pathogens, especially in immunocompromised individuals.

Case report

We present the case of a 73 year-old man with diarrhea, anorexia and fever. In the blood analyses, both aerobic blood culture bottles yielded the growth of Rhodotorula dairenensis. The MALDI-TOF MS score was inadequate to provide an identification, which was achieved by means of molecular techniques. Treatment with an echinocandin was started, but the patient died.

Conclusions

Basidiomycetous yeast genera such as Rhodotorula can cause invasive and severe infections, e.g., fungemia, especially in patients with central venous catheter or another indwelling device.

传统上，hodotorula被认为是非毒性的环境微生物，但现在被认为是重要的人类病原体，特别是在免疫功能低下的个体中。病例报告我们报告一例73岁男性腹泻，厌食和发烧。在血液分析中，两个有氧血培养瓶都产生了daidotorula ensis的生长。MALDI-TOF MS评分不足以提供鉴定，这是通过分子技术实现的。开始使用棘白菌素治疗，但患者死亡。结论担子菌属如红酵母属可引起侵袭性和严重感染，如真菌血症，特别是在中心静脉导管或其他留置装置的患者中。

引用次数: 2

Diversity and adaptation within the genus Malassezia: Bats already have their species 马拉色属的多样性和适应性:蝙蝠已经有了自己的物种

IF 1.9 4区生物学 Q4 MYCOLOGY

Revista Iberoamericana De Micologia

Pub Date : 2020-04-01 DOI: 10.1016/j.riam.2019.12.001

F. Javier Cabañes

引用次数: 2

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Revista Iberoamericana De Micologia

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀